Hemochromatosis subjects as allogeneic blood donors

A prospective study

Susan F. Leitman, Janet N. Browning, Yu Ying Yau, Glorice Mason, Harvey G. Klein, Cathy Conry-Cantilena, Charles D. Bolan

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Persons with hemochromatosis constitute a plentiful and willing source of blood for transfusion. A program was established and evaluated for treating persons with hemochromatosis in a donor center and making their blood available for transfusion. STUDY DESIGN AND METHODS: Phlebotomy therapy was performed free of charge regardless of whether subjects met criteria for allogeneic donation. A Hb level of 12.5 g per dL was used as the threshold for performing phlebotomy, and decreases in the MCV were used to guide the endpoints of therapy. RESULTS: A total of 130 subjects were consecutively enrolled: 74 percent were homozygous for the C282Y mutation in the HFE gene, 76 percent met eligibility criteria for allogeneic donation, and 55 percent were previous blood donors. A median of 20 weekly or biweekly phlebotomies (range, 7-99) were performed before the MCV reached the targeted endpoint of 3 percent below baseline, at which time the ferritin level was less than 30 μg per L and the transferrin saturation was less than 30 percent. The median phlebotomy interval necessary to keep the MCV at this level during maintenance therapy was 10 weeks. No incident seroconversions for agents of transfusion-transmissible disease occurred during 1402 donations. All subjects testing positive for viral agents gave a prior history of deferrable risk. Twenty-seven months after starting the program, hemochromatosis donors were contributing 14 percent of the RBC units collected for allogeneic use. CONCLUSIONS: Hemochromatosis subjects can safely and significantly augment the allogeneic blood supply. Provision of phlebotomy therapy unrestricted by considerations of cost or suitability for donation can improve access to care and remove incentives for incomplete risk disclosure.

Original languageEnglish (US)
Pages (from-to)1538-1544
Number of pages7
JournalTransfusion
Volume43
Issue number11
DOIs
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Phlebotomy
Hemochromatosis
Blood Donors
Prospective Studies
Blood Transfusion
Tissue Donors
Disclosure
Therapeutics
Transferrin
Ferritins
Motivation
Costs and Cost Analysis
Mutation
Genes

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Leitman, S. F., Browning, J. N., Yau, Y. Y., Mason, G., Klein, H. G., Conry-Cantilena, C., & Bolan, C. D. (2003). Hemochromatosis subjects as allogeneic blood donors: A prospective study. Transfusion, 43(11), 1538-1544. https://doi.org/10.1046/j.1537-2995.2003.00570.x

Hemochromatosis subjects as allogeneic blood donors : A prospective study. / Leitman, Susan F.; Browning, Janet N.; Yau, Yu Ying; Mason, Glorice; Klein, Harvey G.; Conry-Cantilena, Cathy; Bolan, Charles D.

In: Transfusion, Vol. 43, No. 11, 11.2003, p. 1538-1544.

Research output: Contribution to journalArticle

Leitman, SF, Browning, JN, Yau, YY, Mason, G, Klein, HG, Conry-Cantilena, C & Bolan, CD 2003, 'Hemochromatosis subjects as allogeneic blood donors: A prospective study', Transfusion, vol. 43, no. 11, pp. 1538-1544. https://doi.org/10.1046/j.1537-2995.2003.00570.x
Leitman SF, Browning JN, Yau YY, Mason G, Klein HG, Conry-Cantilena C et al. Hemochromatosis subjects as allogeneic blood donors: A prospective study. Transfusion. 2003 Nov;43(11):1538-1544. https://doi.org/10.1046/j.1537-2995.2003.00570.x
Leitman, Susan F. ; Browning, Janet N. ; Yau, Yu Ying ; Mason, Glorice ; Klein, Harvey G. ; Conry-Cantilena, Cathy ; Bolan, Charles D. / Hemochromatosis subjects as allogeneic blood donors : A prospective study. In: Transfusion. 2003 ; Vol. 43, No. 11. pp. 1538-1544.
@article{fba2ff7ff4b9403eb6ea7d25fa67c129,
title = "Hemochromatosis subjects as allogeneic blood donors: A prospective study",
abstract = "BACKGROUND: Persons with hemochromatosis constitute a plentiful and willing source of blood for transfusion. A program was established and evaluated for treating persons with hemochromatosis in a donor center and making their blood available for transfusion. STUDY DESIGN AND METHODS: Phlebotomy therapy was performed free of charge regardless of whether subjects met criteria for allogeneic donation. A Hb level of 12.5 g per dL was used as the threshold for performing phlebotomy, and decreases in the MCV were used to guide the endpoints of therapy. RESULTS: A total of 130 subjects were consecutively enrolled: 74 percent were homozygous for the C282Y mutation in the HFE gene, 76 percent met eligibility criteria for allogeneic donation, and 55 percent were previous blood donors. A median of 20 weekly or biweekly phlebotomies (range, 7-99) were performed before the MCV reached the targeted endpoint of 3 percent below baseline, at which time the ferritin level was less than 30 μg per L and the transferrin saturation was less than 30 percent. The median phlebotomy interval necessary to keep the MCV at this level during maintenance therapy was 10 weeks. No incident seroconversions for agents of transfusion-transmissible disease occurred during 1402 donations. All subjects testing positive for viral agents gave a prior history of deferrable risk. Twenty-seven months after starting the program, hemochromatosis donors were contributing 14 percent of the RBC units collected for allogeneic use. CONCLUSIONS: Hemochromatosis subjects can safely and significantly augment the allogeneic blood supply. Provision of phlebotomy therapy unrestricted by considerations of cost or suitability for donation can improve access to care and remove incentives for incomplete risk disclosure.",
author = "Leitman, {Susan F.} and Browning, {Janet N.} and Yau, {Yu Ying} and Glorice Mason and Klein, {Harvey G.} and Cathy Conry-Cantilena and Bolan, {Charles D.}",
year = "2003",
month = "11",
doi = "10.1046/j.1537-2995.2003.00570.x",
language = "English (US)",
volume = "43",
pages = "1538--1544",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Hemochromatosis subjects as allogeneic blood donors

T2 - A prospective study

AU - Leitman, Susan F.

AU - Browning, Janet N.

AU - Yau, Yu Ying

AU - Mason, Glorice

AU - Klein, Harvey G.

AU - Conry-Cantilena, Cathy

AU - Bolan, Charles D.

PY - 2003/11

Y1 - 2003/11

N2 - BACKGROUND: Persons with hemochromatosis constitute a plentiful and willing source of blood for transfusion. A program was established and evaluated for treating persons with hemochromatosis in a donor center and making their blood available for transfusion. STUDY DESIGN AND METHODS: Phlebotomy therapy was performed free of charge regardless of whether subjects met criteria for allogeneic donation. A Hb level of 12.5 g per dL was used as the threshold for performing phlebotomy, and decreases in the MCV were used to guide the endpoints of therapy. RESULTS: A total of 130 subjects were consecutively enrolled: 74 percent were homozygous for the C282Y mutation in the HFE gene, 76 percent met eligibility criteria for allogeneic donation, and 55 percent were previous blood donors. A median of 20 weekly or biweekly phlebotomies (range, 7-99) were performed before the MCV reached the targeted endpoint of 3 percent below baseline, at which time the ferritin level was less than 30 μg per L and the transferrin saturation was less than 30 percent. The median phlebotomy interval necessary to keep the MCV at this level during maintenance therapy was 10 weeks. No incident seroconversions for agents of transfusion-transmissible disease occurred during 1402 donations. All subjects testing positive for viral agents gave a prior history of deferrable risk. Twenty-seven months after starting the program, hemochromatosis donors were contributing 14 percent of the RBC units collected for allogeneic use. CONCLUSIONS: Hemochromatosis subjects can safely and significantly augment the allogeneic blood supply. Provision of phlebotomy therapy unrestricted by considerations of cost or suitability for donation can improve access to care and remove incentives for incomplete risk disclosure.

AB - BACKGROUND: Persons with hemochromatosis constitute a plentiful and willing source of blood for transfusion. A program was established and evaluated for treating persons with hemochromatosis in a donor center and making their blood available for transfusion. STUDY DESIGN AND METHODS: Phlebotomy therapy was performed free of charge regardless of whether subjects met criteria for allogeneic donation. A Hb level of 12.5 g per dL was used as the threshold for performing phlebotomy, and decreases in the MCV were used to guide the endpoints of therapy. RESULTS: A total of 130 subjects were consecutively enrolled: 74 percent were homozygous for the C282Y mutation in the HFE gene, 76 percent met eligibility criteria for allogeneic donation, and 55 percent were previous blood donors. A median of 20 weekly or biweekly phlebotomies (range, 7-99) were performed before the MCV reached the targeted endpoint of 3 percent below baseline, at which time the ferritin level was less than 30 μg per L and the transferrin saturation was less than 30 percent. The median phlebotomy interval necessary to keep the MCV at this level during maintenance therapy was 10 weeks. No incident seroconversions for agents of transfusion-transmissible disease occurred during 1402 donations. All subjects testing positive for viral agents gave a prior history of deferrable risk. Twenty-seven months after starting the program, hemochromatosis donors were contributing 14 percent of the RBC units collected for allogeneic use. CONCLUSIONS: Hemochromatosis subjects can safely and significantly augment the allogeneic blood supply. Provision of phlebotomy therapy unrestricted by considerations of cost or suitability for donation can improve access to care and remove incentives for incomplete risk disclosure.

UR - http://www.scopus.com/inward/record.url?scp=0242440043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242440043&partnerID=8YFLogxK

U2 - 10.1046/j.1537-2995.2003.00570.x

DO - 10.1046/j.1537-2995.2003.00570.x

M3 - Article

VL - 43

SP - 1538

EP - 1544

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 11

ER -